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Abstract
Background: Cardiovascular disease (CVD) is often comorbid with chronic kidney disease (CKD). Small low-density
lipoprotein cholesterol (sdLDL-C) has also been found to increase risk for CVD. The goal of the present study was to
determine the nature of the relationship between sdLDL-C concentration and CVD in patients with CKD.
Methods: One-hundred and forty-five subjects (113 men and 32 women) with CKD (Stage 3 and Stage 4) participated
this retrospective study. The concentration of sdLDL-C was measured in samples from 145 CKD patients between 2010
and 2012 during a four-year follow-up period.
Results: A total of eight fatal cardiovascular events (CVs) and 46 nonfatal CVs were registered in the four-year follow-up
period. Multivariate Cox regression analysis showed that sdLDL-C [1.278, 95 % (1.019–1.598)] and sdLDL-C/LDL-C [2.456,
95 % (1.421–15.784)], at final observation, were independent risks of CVs. A Kaplan-Meier survival analysis showed that
patients with sdLDL-C >38 mg/dl (logrank: 4.375, P = 0.037), and sdLDL-C/LDL-C ratio >0.3 levels (logrank: 11.
94, P = 0.018) were at increased risk for CVs.
Conclusion: The results of this study indicated that for patients suffering CKD, a significant relationship exists
between an elevated sdLDL-C concentration and the risk of cardiovascular disease.
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Background
Chronic kidney disease (CKD) progression is frequently
complicated with dyslipidemia, which is recognized as
the most important risk factor causing cardiovascular
disease (CVD) in CKD patients. Multiple observational
studies have shown that low density lipoprotein choles-
terol (LDL-C) is an effective, independent predictor of
CVD morbidity and mortality; Small dense LDL
(sdLDL) has been associated with increased risk for
CVD in a number of cross-sectional studies [1–4]. This
is most likely because in large quantities, sdLDL
particles are more atherogenic than larger, buoyant
LDL-C particles [2, 5].
Though the pathogenesis for the elevated risk of
CVD in patients with CKD remains elusive, CVD is in-
deed the leading cause of death among patients with
CKD [6–9]. Studies have shown that sdLDL-C is signifi-
cantly higher than LDL-C in patients with coronary ar-
tery disease and have associated it with the incidence of
CVs independently of LDL-C [10, 11]. Accordingly,
sdLDL-C seems to be a major and independent CVD
risk factor.
To date, there has been no prospective study to assess
the association of sdLDL-C with CV onset in patients
with CKD, though doing so is newly possible by virtue
of innovative, fully automated, homogenous assay tech-
niques that now allow for the routine inspection of a
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large number of samples. The present study was con-
ducted in effort to determine whether sdLDL-C is an ef-
fective (and readily assessed) predictive factor of CVD in
CKD patients.
Methods
Subjects and study design
A total of 248 non-dialysis CKD patients (Stage 3 to
Stage 4) who had no history of treatment with lipid-
lowering drugs were enrolled in this study from the
Renal Unit of Wujiang Affiliated Hospital of Nantong
University between December, 2010 and December,
2012. CKD was diagnosed according to the National
Kidney Foundation K/DOQI Guidelines [12]. Exclusion
criteria included severe hepatic disease (n = 3), infectious
disease (n = 6), current treatment for malignancy (n = 4),
and known thyroid disorders (n = 2), lost during follow-
up (n = 13), missing blood examination data (n = 3),
withdrew consent (n = 1), and treatment with lipid-
lowering drugsduring the follow-up period (n = 71).
After these patients were excluded, data from 145 partic-
ipants was ultimately included in the study. The mean
age of participants was 65.2 ± 11.3 years; the individuals
ranged in age from 50 to 72 years. Thirty-four of these
participants had a verifiable medical history of CVD at
the time of enrollment. Of these 34, 3 had a history of
stroke, 26 had a history of previous myocardial infarc-
tion, and 5 had a history of peripheral vascular disease.
Eighty healthy subjects with similar gender, age and
sdLDL-C characteristics as the patient groups served as
a control group (mean age 64.3 ± 10.8 years, ranging
from 52 to 71 years.)
Blood samples were collected and centrifuged im-
mediately after the subjects had fasted for 12 h. The
body mass index (BMI), smoking history, and medical
history of each participant were collected. A diagnosis
of hypertension was given to participants who showed
a systolic blood pressure (SBP) ≥140 mmHg, a dia-
stolic blood pressure (DBP) ≥90 mmHg after the first
three measurements, or if they had a history of taking
anti-hypertensive medications [13]. Diabetes was the
diagnosis for a fasting serum glucose registering
≥7.0 mmol/L (126 mg/dL) or for those with a history
of anti-diabetes medications [14]. Dyslipidemia was
defined as triglyceride (TG) ≥150 (mg/dl), LDL-C
≥140 (mg/dl), or high-density lipoprotein cholesterol
(HDL-C) <40 (mg/dl) [15]. We calculated the estimated
glomerular filtration rate (eGFR) by using the Modifica-
tion of Diet in Renal Disease (MDRD) equation:
186 × (serum creatinine)− 1.154 × age− 0.203 × (0.742 forfe-
males) [16]. All relevant data was evaluated between Octo-
ber and December of 2014. The endpoints of the present
study were date of the first CV onset during the follow-up
period, death, or the patient’s last visit to the Wujiang
Affiliated Hospital of Nantong University. CVs were
defined and registered as listed in Table 1 during the
follow-up.
Laboratory measurements
We measured the above parameters for all subjects at
the onset of CVs yearly during the follow-up period.
Laboratory examination results including serum TG,
total cholesterol (TC), HDL-C, LDL-C, fasting blood
glucose (FBG), apolipoproteins A1 (ApoA1), B (ApoB),
and glycated hemoglobin (HbA1c) were measured via
HPLC method [17] and hsCRP was estimated via immu-
noturbidimetry method using a commercial Beckman
Synchron DxC 600 fully automated analyser kit (USA). An
sdLDL-EX Seiken kit was used for quantitative determin-
ation of sdLDL-C in samples according to the manufac-
turer’s instructions [18].
Statistical analyses
All statistical analyses were performed in SAS 9.1 soft-
ware (SAS Institute, Cary, NC, USA). Baseline character-
istics were compared between the Event and Non-event
groups using a t-test for parametric variables, Wilcoxon
tests for non-parametric variables, and Chi-square tests
for categorical variables. Differences in cumulative inci-
dence were assessed by log-rank tests in subjects divided
into two groups based on the median levels (38 mg/dl)
of sdLDL-C. The Cox proportional hazard regression
model was used to identify the most significant factors,
adjust them by sex, and determine which differed statis-
tically between event and event-free subjects; P < 0.05
was considered statistically significant.





Patients (n = 145) Control (n = 80)
Non-fatal Fatal Non-fatal Fatal
Heart failure 1 7 0 1
Ischemic stroke 2 0 0 0
Hemorrhagic stroke 4 0 0 0
Acute coronary syndrome 21 1 2 0
Coronary or any peripheral
arterial revascularization
18 0 4 0
Total 54 7
Events% 37.2 % 8.8 %
Pa <0.001
Data are presented as the number and its percentage (%). Percentage = the
number of each individual category divided by n
aindicates the comparison of percentage between Patients group and
Control group
Shen et al. BMC Nephrology  (2016) 17:143 Page 2 of 7
Results
As discussed above, Chi-square analysis was used in this
study to compare the distribution of CKD-Stage III and
CKD-Stage IV between Event and Non-event groups. As
shown in Fig. 1, the distribution was notably different;
the percentage of CKD-Stage III in the Non-event group
was significantly higher than that of the Event group
(p < 0.029). Table 1 shows that the prevalence rates of
CV outcomes were significantly higher in the patient
groups than the healthy control group (37.2 % vs.
8.7 %, P < 0.001). By comparison of the outcomes of
the general and laboratory characteristics between the two
groups (Event vs. Non-event) showed that CKD patients
with CVs had significantly higher prevalence of diabetes
mellitus and hypertension. These differences grew more
intense with age, as well. HbA1c, sdLDL-C, LDL-C/HDL-
C, and sdLDL-C/LDL-C were higher in the Event group
than the Non-event group at baseline. ApoA-I, eGFR, and
HDL-C levels were significantly lower in the Event group,
Fig. 1 CVD events outcome in CKD-Stage IIIand CKD-StageIV.
* indicates that Chi-square analysis was used to compare the distri-
bution of CKD-Stage III and CKD-Stage IV between Event group and
Non-event group
Table 2 The clinical characteristics at baseline of the enrolled patients
Variable All CVs Non- CVs Pa
(n = 145) (n = 54) (n = 91)
Men 113 (77.9 %) 45 (83.3 %) 68 (74.7 %) 0.227
Age(years) 65.2 ± 11.3 68.5 ± 10.5 63.2 ± 11.5 0.006
Body mass index(kg/m2) 23.9 ± 3.2 24.5 ± 3.3 23.6 ± 3.2 0.108
History of cardiovascular disease
Previous myocardial infarction 26 (17.9 %) 10 (18.5 %) 16 (17.6 %) 0.887
Stroke 3 (2.1 %) 1 (1.9 %) 2 (2.2 %) 0.998
Peripheral vascular disease 5 (3.4 %) 2 (3.7 %) 3 (3.3 %) 0.998
Cardiovascular disease risk factors
Hypertension 116 (80.0 %) 48 (88.9 %) 68 (74.7 %) 0.039
Diabetes mellitus 65 (44.8 %) 32 (59.3 %) 33 (36.3 %) 0.007
Dyslipidemia 123 (84.8 %) 46 (85.2 %) 77 (84.6 %) 0.926
Smoking, current or former 63 (43.4 %) 23 (42.6 %) 40 (44.0 %) 0.873
Family history 26 (17.9 %) 12 (22.2 %) 14 (15.4 %) 0.299
Etiology of CKD
Diabetes 40 (27.6 %) 14 (25.9 %) 26 (28.6 %)
Glomerulonephritis 22 (15.2 %) 7 (13.0 %) 15 (16.5 %)
Hypertension 36 (24.8 %) 16 (29.6 %) 20 (22.0 %) 0.875
Polycystic kidney disease 5 (3.4 %) 2 (3.7 %) 3 (3.3 %)
Unknown 42 (29.0 %) 15 (27.8 %) 27 (29.7 %)
Medication
Angiotensin receptor blocker 65 (44.8 %) 24 (44.4 %) 41 (45.1 %) 0.943
Angiotensin converting enzyme inhibitors 27 (18.6 %) 14 (25.9 %) 13 (14.4 %) 0.082
Insulin 7 (4.8 %) 3 (5.6 %) 4 (4.4 %) 0.753
Antiplatelet 71 (48.9 %) 25 (46.3 %) 46 (50.6 %) 0.620
Data are presented as mean ± SD or the number and its percentage (%). Percentage = the number of each individual category divided by n
Abbreviation: CVs cardiovascular events
aindicates the comparison of mean or percentage between Event group and Non-event group
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and ApoB, Non-HDL-C, and LDL-C were similar between
the two groups (Tables 2 and 3).
The unadjusted Cox regression analysis showed that the
association was stronger for sdLDL-C/LDL-C than
sdLDL-C, age, LDL-C/HDL-C, eGFR, HbA1c, or ApoA-I
as they affected the incidence of CVs at the final observa-
tion. Increase in LDL-C was not significant in terms of in-
creased risk of CVs, however. After risk adjustment in the
multivariate Cox regression analysis, which included the
significant predictors above and the marginally significant
predictor of CVs in the univariate model, we confirmed
that sdLDL-C/LDL-C had stronger impact than sdLDL-C,
age, or HbA1c at final observation. Moreover, LDL-C/
HDL-C was not found to be a statistically significant inde-
pendent risk factor for CVs (Table 4).
During a median follow-up period of 2.3 years, Kaplan-
Meier survival analysis results showed that sdLDL-C levels
were significantly associated with CV incidence in our
participants: Patients with sdLDL-C >38 mg/dl levels were
at increased risk for CVs (logrank: 4.375, P = 0.037) as
shown in Fig. 2, as were patients with sdLDL-C/LDL-C ra-
tio >0.3 (logrank: 11.94, P = 0.018) as shown in Fig. 3.
Discussion
The results of multivariate Cox regression analysis,
which included the significant predictors and the mar-
ginally significant predictors of CVs in the univariate
model, showed that elevated sdLDL-C concentration
and sdLDL-C/LDL-C can be associated with increased
CVD risk in CKD patients. We also found that HR was
significant after multivariable adjustment and by analysis
including gender, age, HbA1c, eGFR, hs-CRP, and other
lipid risk factors in Models 1 and 2; sdLDL-C, HbA1c,
and sdLDL-C/LDL-C concentrations did remain an in-
dependent risk predictor for CVs. In our study, partici-
pants with elevated HbA1c levels were the most at risk
for CVs, suggesting that without proper diabetes control,
there is an increased risk for CVs. An increase in
sdLDL-C/LDL-C also indicated CV risk. An imbalance
of cholesterol-poor sdLDL and cholesterol-rich large
LDL led to a risk of CVs for patients who did not receive
any lipid-lowering medications during the follow-up
period. There is evidence that sdLDL formation is re-
lated to postprandial hyperglycemia and hyperlipidemia,
both of which can lead to CVs. Additionally, the sdLDL-
C/LDL-C ratio is another risk factor for CVs in CKD pa-
tients. Patients with CKD have elevated sdLDL-C/LDL-C,
over sdLDL-C, and declining eGFR, are at risk for CVs.
Patients with CKD have significantly increased risk for
cardiovascular complications. Traditional risk factors fail
to fully explain the high incidence of CVD in CKD pa-
tients. Similarly, traditional lipid measures are not suffi-
cient for predicting cardiovascular outcomes in CKD
patients [1, 19–21]. In accordance with the results pre-
sented here, previous studies have shown that sdLDL-C
is significantly higher than LDL-C in patients with
Table 3 The laboratory characteristics at baseline of the enrolled patients
Variable All CVs Non- CVs P
(n = 145) (n = 54) (n = 91)
LDL–C(mg/dl) 119.2 ± 31.2 120.1 ± 30.2 118.6 ± 32.4 0.783
sdLDL–C(mg/dl) 37.9 ± 21.3 43.4 ± 26.5 34.7 ± 20.2 0.027
lbLDL–C(mg/dl) 80.4 ± 25.5 75.2 ± 25.4 83.5 ± 25.2 0.058
sdLDL–C/LDL–C 0.32 ± 0.13 0.36 ± 0.16 0.29 ± 0.12 0.003
TG(mg/dl) 134.5 (91.3–180.5) 132 (87.5–176.3) 135.3 (93.2–185.6) 0.982
TC(mg/dl) 190.1 ± 34.9 183.9 ± 30.4 193.8 ± 34.8 0.085
HDL–C(mg/dl) 45.7 ± 14.2 42.3 ± 14.8 47.7 ± 13.2 0.024
Non-HDL–C(mg/dl) 142.6 ± 33.6 142.8 ± 31.8 142.5 ± 35.4 0.959
LDL–C/HDL–C 2.84 ± 1.12 3.11 ± 1.16 2.68 ± 1.06 0.024
Apo A-I (mg/dl) 119.0 ± 23.2 111.7 ± 22.7 123.3 ± 22.7 0.003
Apo B(mg/dl) 93.0 ± 22.3 95.4 ± 37.3 91.6 ± 20.7 0.431
FBG (mg/dl) 116.7 ± 36.2 121.6 ± 37.3 113.8 ± 35.8 0.214
HbA1c(%) 6.41 ± 1.23 6.85 ± 1.36 6.15 ± 1.08 <0.001
hs-CRP (mg/dl) 0.39 (0.16–1.52) 0.53 (0.43–1.65) 0.31 (0.15–1.48) 0.069
eGFR(ml/min/1.73 m2) 50.3 ± 16.5 45.6 ± 15.8 53.1 ± 17.7 0.011
Normal Data are presented as mean ± SD, and Median (Q1-Q3) are used for abnormal data
lbLDL-C (mg/dl) = LDL-C (mg/dl) − SdLDL-C (mg/dl)
Abbreviation: LDL-C low-density lipoprotein cholesterol, sdLDL-C small dense LDL-C, lbLDL-C large buoyant LDL-C, TG triglyceride, TC total cholesterol, HDL-C high-
density lipoprotein cholesterol, Apo apolipoprotein, FBG fasting blood glucose, HbAlc hemoglobin A1c, eGFR estimated glomerular filtration rate, hs-CRP high sensi-
tivity C-reaction protein, CVs cardiovascular events
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coronary artery disease and have associated it with the
incidence of CVs independently of LDL-C [10, 11]. As
discussed above, we also failed to observe any significant
impact on CV risk with increased LDL-C. Our multiple
regression analysis results also suggested that the com-
mon blood lipid and lipoprotein index measures fail to
accurately predict CVs, and that increased sdLDL is ap-
parently the most effective atherogenic risk factor in
CKD patients [22–25].
It is worth mentioning that sdLDL, which has greater
susceptibility to oxidation, is already regarded as a risk
marker for CVD [26–32]. There is scientific evidence
that sdLDL particles are highly atherogenic and can be a
biomarker of CVD [30–32]. Traditional methods of de-
tecting sdLDL are generally ineffective, however, as they
require laborious and lengthy assay processes [33, 34].
The results of this study support the role of sdLDL-C in
regards to CVD risk, and also suggest that routine detec-
tion is indeed possible via a new, fully automated,
homogenous assay technique.
This study had several potential limitations. First, pa-
tients with CVs had more diabetes and hypertension,
and these factors were not evaluated. Second, the effects
of insulin therapy were not investigated. The small
Fig. 2 Kaplan-Meier event-free survival curves according to sdLDL-C
levels were above or below the median (38 mg/dl)
Fig. 3 Kaplan-Meier event-free survival curves according to sdLDL-C/
LDL-C ratio were above or below the median (0.3)
Table 4 Univariate and multivariate Cox,s proportional hazard analysis predicting for cardiovascular events
Variable Univariate model Multivariate model
HR 95 % CI Model 1 Model 2
HR 95 % CI HR 95 % CI
Age 1.251 (1.145–1.590) 1.204 (1.032–1.578) 1.214 (1.143–1.580)
Men 0.801 (0.488–1.313) 0.774 (0.555–1.086) 0.776 (0.553–1.087)
sdLDL–C 1.294 (1.026–1.633) 1.275 (1.016–1.596) 1.280 (1.020–1.624)
sdLDL–C/LDL–C 2.526 (1.653–22.5904) 2.450 (1.420–15.630) 2.445 (1.402–14.521)
LDL–C 1.015 (0.908–1.131) - -
HDL–C 0.721 (0.450–1.130) 0.822 (0.475–1.346) -
Non-HDL–C 1.045 (0.912–1.118) - -
LDL–C/HDL–C 1.167 (1.013–1.323) 1.012 (0.913–1.124) -
Apo A-I 0.963 (0.941–0.992) - 0.982 (0.943–1.142)
HbA1c 1.215 (1.133–1.684) 1.204 (1.101–1.504) 1.135 (1.103–1.497)
eGFR 0.965 (0.926–0.992) 0.979 (0.936–1.002) -
hs-CRP 1.007 (0.912–1.113) 1.071 (0.941–1.085) -
Abbreviations are the same as those for Table 3. Model1 was adjusted age, gender, sdLDL–C, sdLDL–C/LDL–C,HDL–C, LDL–C/HDL–C, HbA1c, eGFR, hs-CRP. Model
2 was adjusted age, gender, sdLDL–C, ApoA-I,sdLDL–C/LDL–C,HbA1c. Bold numbers: statistically significant
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sample size and relatively brief follow-up period were
also less than ideal. Finally, the cohort may not be com-
pletely representative of the CKD population due to the
exclusion of patients treated with lipid-lowering medica-
tion. Future studies should focus on resolving these is-
sues, especially with a larger sample size.
Conclusion
The results of this study indicated that for patients suf-
fering CKD, a significant relationship exists between an
elevated sdLDL-C concentration and the risk of cardio-
vascular disease.
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